RETA - Reata Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Performance Price Targets & Ratings Chart Insider Trading

RETA is currently covered by 12 analysts with an average price target of $183.14. This is a potential upside of $10.78 (6.25%) from yesterday's end of day stock price of $172.36.

Reata Pharmaceuticals's activity chart (see below) currently has 110 price targets and 102 ratings on display. The stock rating distribution of RETA is 25% HOLD and 75% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.02% with an average time for these price targets to be met of 175.07 days.

Highest price target for RETA is $172.5, Lowest price target is $80, average price target is $183.14.

Most recent stock forecast was given by CHARLES DUNCAN from CANTOR FITZGERALD on 15-Aug-2023. First documented stock forecast 20-Jun-2016.

Currently out of the existing stock ratings of RETA, 10 are a HOLD (25%), 30 are a BUY (75%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

172

$-0.36 (-0.21%)

145

6 months 15 days ago

9/14 (64.29%)

$2.87 (1.70%)

152

Hold

172

$-0.36 (-0.21%)

98

7 months ago

6/7 (85.71%)

$5.9 (3.55%)

237

Buy

172.5

$0.14 (0.08%)

140

7 months ago

1/2 (50%)

$6.4 (3.85%)

22

Hold

127

$-45.36 (-26.32%)

53

6 months 30 days ago

13/22 (59.09%)

$-38.58 (-23.30%)

244

Hold

85

$-87.36 (-50.68%)

40

6 months 30 days ago

8/12 (66.67%)

$-80.58 (-48.67%)

216

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RETA (Reata Pharmaceuticals) average time for price targets to be met?

On average it took 175.07 days on average for the stock forecasts to be realized with a an average price target met ratio 54.02

Which analyst has the current highest performing score on RETA (Reata Pharmaceuticals) with a proven track record?

MADHU KUMAR

Which analyst has the most public recommendations on RETA (Reata Pharmaceuticals)?

Madhu Kumar works at GOLDMAN SACHS and has 9 price targets and 6 ratings on RETA

Which analyst is the currently most bullish on RETA (Reata Pharmaceuticals)?

Matthew Kaplan with highest potential upside - $138.97

Which analyst is the currently most reserved on RETA (Reata Pharmaceuticals)?

Yatin Suneja with lowest potential downside - -$97.36

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?